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Abstract
Nanomaterials are relatively new and unconventional materials with many useful properties, but their effects on
biological systems are poorly understood. Nanoclay is a general term for layered mineral silicate nanoparticles that
are ideally suited for use in clay-based nanocomposites. The potential biological hazards of nanoclays have not
been addressed, however. Therefore, we investigated the in vivo effects and drug interactions of nanoclays. In mice,
administration of nanoclay particles via the tail vein led to acute liver injury. Co-administration of nanoclay and
carbon tetrachloride, paraquat, or cisplatin resulted in both liver and kidney injury. Our findings thus indicate that
nanoclay particles are potentially hepato- and nephrotoxic.
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Background
Recent advances in technologies for reducing the size of
materials have led to the development of innovative nano-
materials with many potential applications. Nanomaterials
are frequently used in microelectronics, cosmetics, and
sunscreens, and their potential use in drug-delivery
systems is being investigated [1–3]. Compared with
micromaterials, nanomaterials have various unique physi-
cochemical qualities related to size, surface structure,
solubility, and aggregation characteristics. Thus, the
reduction in particle size from the micro- to nanoscale
could be beneficial in many industrial and scientific
applications.
Despite their potential benefits, nanomaterials can
exhibit toxicities not associated with micromaterials,
making it essential to understand the biological activity
and potential toxicity of nanomaterials [4, 5]. Conside-
rable recent research has focused on the human health
effects of inhalation of nanomaterials, and a number of
risks have been identified. For example, occupational
exposure to quartz, mineral dust particles, and asbestos
have been shown to induce inflammation, fibrosis, and
cytotoxicity in the lungs [6, 7]. Animal studies have
revealed that carbon nanotubes are potentially carci-
nogenic in the lungs [8]. Silica nanoparticles reportedly
induce liver injury and can penetrate the blood-brain
barrier and enter the brain [9, 10]. Due to differences in
the chemical composition of many nanoparticles, their
toxicity varies as well [11]. It is possible that chemicals
that are otherwise generally nontoxic to humans can be
rendered toxic if presented via nano-sized particles.
Due to their viscosity, clay soils are capable of
retaining considerable amounts of water. Clays have
been used since ancient times as raw materials for
ceramics [12], and they are composed of layered
silicate minerals such as Si-O4, Al-O, and Mg-O
arranged in a planar octahedron configuration. The
nanoclays used in this study, Si-O4 and Al-O, are
montmorillonites that form a continuous sheet-like
conformation. One side of the sheet-like plane
(100 nm or less) of the clay mineral is nanoclay.
Clays are used in a wide variety of products, including
paints, cosmetics, and pharmaceuticals [13]. Compared
with clays, nanoclays exhibit a number of advantageous
properties, including higher workability, mechanical
strength, and heat resistance. As such, it is expected that
applications for nanoclays in products will increase in
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the future [14, 15]. However, as clay minerals are gene-
rally considered safe to humans, there are no reports
examining the potential toxicity of nanoclays. In this
study, therefore, the potential toxicity of nanoclay
particles was evaluated using acute toxicity testing and
drug interaction analyses in mice.
Methods
Materials
Nanoclay particles were obtained from Sigma-Aldrich
Co. (St. Louis, MO). The nanoclay particles were in the
form of a powder having a layered particle size with one
side of 1 nm. For injection, nanoclay particles were
dispersed at a concentration of 20 mg/ml in medical
water for injection (Fuso Pharmaceutical Industries, Ltd.,
Japan). The nanoclay particles suspended in the injection
water were then stirred and sonicated for 10 min.
Analysis of the size distribution of the particles, as deter-
mined using a Zetasizer (Sysmex Co., Kobe, Japan)
(Fig. 1), revealed an average particle diameter of 57.8 ±
12.3 nm for peak 1 and an average particle diameter of
648.3 ± 232.2 nm for peak 2. In addition, the peak 1
volume was 43.6% and the peak 2 volume was 56.4%
(Fig. 1). The suspensions were thoroughly dispersed by
sonication before use and then diluted with water. An
equal volume of suspension was injected for each treat-
ment. Paraquat and cisplatin were dissolved in saline
and stored at −20 °C until use. Carbon tetrachloride was
dissolved in olive oil. All reagents used were of research
grade. Medical water (Fuso Pharmaceutical Industries,
Ltd., Japan), which was used as the solvent for nanoclay
particles, was used as the vehicle control.
Animals
Eight-week-old BALB/c male mice were purchased from
Funabashi Farm Co., Ltd. (Chiba, Japan). Animals were
maintained in a controlled environment (temperature:
23 ± 1.5 °C; 12-h light/dark cycle) with free access to
standard rodent chow and water. The mice were given
1 week to acclimate before the experiments were
conducted. The experimental protocols conformed to
the ethical guidelines of the Teikyo Heisei University
Graduate School of Pharmaceutical Sciences, compiled
from the Guidelines for Animal Experimentation of the
Japanese Association for Laboratory Animal Sciences.
Biochemical Analyses
Serum alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) are enzymes that leak into the
blood during hepatic injury and are important indicators
of liver injury [16]. Blood urea nitrogen (BUN) is an
index to be inspected when the kidneys are working
normally, and increases in BUN values are a measure of
deterioration of the kidney function [17]. Serum ALT,
AST, and BUN were measured using commercially avail-
able kits (Wako Pure Chemical Industries) according to
the manufacturer’s protocols. Briefly, collected serum
(10 ml) was combined with 1 ml of color A reagent (in-
cluding urease) and incubated at 37 °C for 15 min.
Following the addition of 1 ml of color B reagent, the
sample was incubated at 37 °C for 10 min. Absorbance
was measured at a wavelength of 570 nm.
Histologic Analyses
At 24 h after dose administration, animals were sacri-
ficed, and the livers were removed and fixed with 4%
paraformaldehyde. Following processing and sectioning,
thin tissue sections were stained with hematoxylin and
eosin for histologic observation.
Statistical Analyses
Statistical analyses were performed with Microsoft Excel
with the Statcel add-in (EMS Publication Co., Ltd.,
Saitama, Japan). All data are presented as means ± stan-
dard error of the means. The significance of differences
between the control and experimental groups was
assessed using the Dunnett’s test. A P value <0.05 was
considered indicative of statistical significance.
Fig. 1 Results of particle diameter measurement of nanoclay particles. The average nanoclay particle diameter of peak 1 was 57.8 ± 12.3 nm, and
the average nanoclay particle diameter of peak 2 was 648.3 ± 232.2 nm
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Results and Discussion
We initially examined the dose dependence of the liver
toxicity of nanoclay particles. Acute liver injury was
observed at the maximum dose of 20 mg/kg of nanoclay
particles (Fig. 2a, b). Hematoxylin and eosin staining of
liver tissue indicated extensive injury in mice adminis-
tered with 20 mg/kg of nanoclay particles (Fig. 2c, d).
We next investigated whether there are interactions
between chemicals and nanoclay particles. To prevent
interactions between the test chemicals and nanoclay
particles prior to administration and absorption, the
chemicals were injected intraperitoneally, and the
nanoclay particles were injected intravenously. Carbon
tetrachloride is known to induce hepatic injury following
intraperitoneal administration [18]. We therefore admin-
istered carbon tetrachloride to mice at a dose that does
not induce hepatic injury (0.01 ml/kg). Treatment with
both carbon tetrachloride and nanoclay particles caused
significant toxicity, with most of the toxicity associated
with the nanoclay particles. Co-administration of carbon
tetrachloride and nanoclay particles (5 mg/kg) resulted
in increases in serum ALT and AST levels (Fig. 3).
We also investigated the potential impact of interaction
with paraquat on the toxicity of nanoclay particles. Para-
quat is one of the most widely used and highly toxic
herbicides. Co-administration of paraquat (50 mg/kg) and
nanoclay particles (5 mg/kg) led to synergistic significant
elevations in serum ALT, and AST levels compared with
nanoclay particles and paraquat administered alone
(Fig. 4a). Serum BUN levels were also significantly elevated
following co-administration of nanoclay particles and
paraquat (Fig. 4b). When nanoclay particles and paraquat
were administered at the same time, ALT increased from
41.5 in the nanoclay particles alone group and from 48.3
in the paraquat alone group to 126.6. AST increased from
257.6 in the nanoclay particles alone group and 354.6 in
the paraquat alone group to 634.1. By simultaneous ad-
ministration of nanoclay and paraquat, the rise in ALT was
synergistic and the rise in AST was additive. It is necessary
to examine the mechanism of exacerbation of liver injury
by co-administration of nanoclay particles and paraquat.
We also investigated the interaction between cisplatin
and nanoclay particles. Administration of cisplatin
causes a variety of adverse effects, such as renal and
hepatic failure [19, 20]. Co-administration of cisplatin
(80 μmol/kg) and nanoclay particles (5 mg/kg) produced
a synergistic elevation in serum levels of ALT (from 16.3
[control] to 611.7 KU) and AST (from 50.4 [control] to
802.6 KU) (Fig. 5a). Serum BUN levels increased from
30.4 (control) to 90.5 mg/ml (Fig. 5b).
Fig. 2 Dose dependence of nanoclay particle-induced liver injury. Serum levels of the liver enzymes alanine aminotransferase (ALT) (a) and aspartate
aminotransferase (AST) (b) were determined using commercially available kits (see Biochemical analyses section) 24 h after intravenous administration
of nanoclay particles at the indicated doses. Histologic analyses of tissues of nanoclay particle-treated mice. At 24 h after administration of vehicle (c)
or nanoclay particles (d), tissues were collected, fixed with 4% paraformaldehyde, sectioned, and stained with hematoxylin and eosin. Data are
presented as mean ± standard error of the mean (n = 4). Significant difference (*P < 0.05, **P < 0.01) compared with the vehicle-treated group
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We were able to induce acute liver injury by adminis-
tering nanoclay particles via the tail vein in mice. Our
study is also the first to report liver injury induced by
co-administration of nanoclay particles and carbon
tetrachloride, paraquat, or cisplatin and kidney injury in-
duced by co-administration of nanoclay particles and
paraquat or cisplatin.
Suspension of the montmorillonite nanoclay particles
in an aqueous solution resulted in the formation of
aggregates with an average particle diameter of 57.8 ±
12.3 nm and 648.3 ± 232.2 nm. However, approximately
46% of the dispersed nanoclay particles exhibited a par-
ticle size of ≤100 nm (Fig. 1). The particle size of the
nanoclay suspension before sonication was 625 ±
147.6 nm (Additional file 1: Figure S1). Approximately
54% of nanoclay particles suspended by sonication
exhibited a size of <100 nm. This result indicates that at
least some of the nanoclay particles did not aggregate.
We tried to develop a suspension method in which
nanoclay particles of 100 nm would be uniformly dis-
persed, but these efforts were unsuccessful. In the future,
it will be necessary to develop a suspension process that
does not promote aggregation of the nanoclay particles.
Previously, we reported that hepatic injury was
induced by combining silica nanoparticles and polystyr-
ene nanoparticles with carbon tetrachloride or paraquat
[9, 21]. We think that it is rare for a nanoclay particles
and carbon tetrachloride or paraquat to be used together
in real-world situations as they were in this experiment.
However, it is possible that hepatic injury may occur by
using a liver injury–inducing chemical substance and
nanoclay particles in combination. Furthermore, it is
necessary to consider combinations of various liver
injury-inducing chemicals and nanoclay particles.
Acute liver injury was induced following administration
of 10 or 20 mg/kg of nanoclay particles to mice via the
Fig. 3 Effect of co-administration of nanoclay particles on carbon
tetrachloride-induced toxicity. Mice were injected intraperitoneally with
carbon tetrachloride at 0.01 ml/kg together with intravenous injection
of vehicle or nanoclay particles (5 mg/kg). At 24 h post-injection, serum
levels of the liver enzymes alanine aminotransferase (ALT, open bars)
and aspartate aminotransferase (AST, solid bars) were determined using
commercially available kits (see Methods). Data are representative of
three independent experiments and are presented as the mean ±
standard error of the mean (n = 4). Significant difference (*P < 0.05)
between vehicle- and carbon tetrachloride-treated groups
Fig. 4 Effect of nanoclay particles (NC) on paraquat (PQ)-induced
toxicity. Mice were injected intraperitoneally with PQ at 50 mg/kg
together with intravenous injection of vehicle or NC (5 mg/kg). a At
24-h post-injection, serum levels of the liver enzymes alanine
aminotransferase (ALT, open bars) and aspartate aminotransferase
(AST, solid bars) were determined using commercially available kits
(see Methods). b Plasma levels of blood urea nitrogen (BUN). Data
are representative of three independent experiments and are
presented as mean ± standard error of the mean (n = 4). Significant
difference (*P < 0.05, **P < 0.01) between vehicle- and
PQ-treated groups
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caudal vein (Fig. 1). BUN levels, however, did not in-
crease, and no kidney injury was observed (data not
shown). In addition, hematoxylin-eosin staining of the
lung tissue of mice treated with nanoclay particles
provided evidence of lung injury (data not shown).
These data suggest that administration of nanoclay
particles causes liver injury. Previously, we reported
that silica nanoparticles of 70 nm diameter accumu-
late in the liver, leading to acute liver injury [22].
Yoshida et al. reported that silica nanoparticles are
distributed to both the liver and the brain [23]. In
addition, Yu et al. reported that silica nanoparticles
accumulate in the liver and spleen in mice [24].
Based on these reports, it is reasonable to conclude
that the accumulation of nanoclay particles in the
liver would also induce liver injury in mice. Future
studies should focus on the correlation between liver
injury and the amount of nanoclay particles that
accumulate in that organ.
We also investigated the combined effects of various
chemicals on nanoclay particle-induced toxicity and found
that carbon tetrachloride, cisplatin, and paraquat exhibit
synergistic toxic effects with nanoclay particles. Liver
injury induced by carbon tetrachloride, paraquat, or
cisplatin is caused by oxidative stress [25, 26]. Micro- or
nano-sized clays also reportedly induce the production of
reactive oxygen species (ROS) in vivo [27]. Increased pro-
duction of ROS following co-administration of nanoclay
particles and chemicals is also consistent with liver injury
following co-administration. We will perform further bio-
chemical and comprehensive analyses, such as proteomic
and genomic studies, to elucidate the mechanism of these
synergistic effects.
Conclusions
In summary, we demonstrated that nanoclay particles can
cause liver damage and that this effect can be synergistically
exacerbated as a result of interactions with hepatotoxic
chemicals or drugs. Further studies based on these data will
be required to fully elucidate the toxicologic profiles of
nanoparticles proposed for use in human medicine.
Additional file
Additional file 1: Supplementary Figure 1. (PPTX 49 kb)
Abbreviations
ALT: Alanine aminotransferase, AST: aspartate aminotransferase; BUN: Blood
urea nitrogen; ROS: Reactive oxygen species
Acknowledgements
The authors thank all members of the laboratory for their useful comments
and discussions.
Authors’ Contributions
KI (Isoda), YS, KI (Isama), and TN designed the study and wrote the Results
and Discussion. YT and IT prepared samples. KI (Isoda), RN, and TH
performed the experiments. KI (Isoda) and II wrote the manuscript.
All authors read and approved the final manuscript.
Competing Interests
The authors declare that they have no competing interests.
Ethics Approval
The experimental protocols conformed to the ethical guidelines of the
Teikyo Heisei University Graduate School of Pharmaceutical Sciences,
compiled from the Guidelines for Animal Experimentation of the Japanese
Association for Laboratory Animal Sciences.
Fig. 5 Effect of nanoclay particles (NC) on cisplatin (CDDP)-
induced toxicity. Mice were injected intraperitoneally with CDDP
at 80 μmol/kg together with intravenous injection of vehicle or
NC (5 mg/kg). a At 24-h post-injection, serum levels of the liver
enzymes alanine aminotransferase (ALT, open bars) and aspartate
aminotransferase (AST, solid bars) were determined using
commercially available kits (see Methods). b Plasma levels of
blood urea nitrogen (BUN). Data are representative of three
independent experiments and are presented as the mean ±
standard error of the mean (n = 4). Significant difference
(**P < 0.01) between the vehicle- and CDDP-treated groups
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